ClinicalTrials.gg

Program

SYS6023

A development code.

Its studies are mostly in Breast Neoplasms, led by CSPC Pharmaceutical Group.

Furthest: phase 2, since May 13, 20262 company-led studies, 2 open or runningNext primary completion: Nov 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Group22 open or runningphase 2since May 13, 2026Jul 14, 2025Nov 30, 2027phase 2 · NCT07597629

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 14, 2025First study: phase 1 study in Advanced Solid TumorFirst studyNCT07110883 · 400 planned · China
  2. May 13, 2026Phase 2 study in Advanced Breast CancerPhase 2 reachedNCT07597629 · 36 planned · China

Ahead

  1. Nov 30, 2027Primary completion: phase 2 study in Advanced Breast CancerNCT07597629

TargetBeta

ERBB3 →read by rule
“SYS6023 is a novel antibody-drug conjugate (ADC) targeting HER3, administered via intravenous infusion.”study text, by rule · the study

Other programs on ERBB3

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
patritumab deruxtecanMerckphase 317
beruzatatug pelitecanruleMediLink Therapeutics (Suzhou)phase 39
ruzaltatug rezetecanJiangsu HengRui Medicinephase 38
JSKN016ruleAlphamab Oncologyphase 35
Anti-HER3/Anti-MUC1 Bispecific Antibody-drug Conjugate DM002rulexadcera-biopharmaceutical-suzhou-co-ltdphase 21
Anti-HER3/Exatecan Antibody-drug Conjugate ENV-501rulehummingbird-biosciencephase 21
Anti-EGFR/Anti-HER3 Bispecific Antibody-drug Conjugate AVZO-1418ruleavenzo-therapeutics-incphase 21
KHN922ruleChengdu Kanghong Pharmaceutical Groupphase 21
CS5007ruleCStone Pharmaceuticalsphase 11
JSKN016HCruleAlphamab Oncologyphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07597629Advanced Breast Cancer · China2RecruitingNov 30, 202736
NCT07110883Advanced Solid Tumor · China1RecruitingOct 31, 2026400

How it is read

Names in the registry

  • “SYS6023”, 2 entries

Codes read as this program: SYS6023.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.